CVS Health announced today that Amgen’s Repatha will be the only PCSK9 inhibitor on the CVS/Caremark formulary. This gives Amgen its first big win among the pharmacy benefits managers against Sanofi’s Praluent in the battle over the market for the powerful but expensive new cholesterol-lowering drugs. Previously Express Scripts had announced that both drugs would be placed…
Amgen’s Repatha Beats Out Competitor For Spot On CVS/Caremark Formulary
November 23, 2015 by Leave a Comment
New Cholesterol Drugs Not Breaking The Bank– Yet
October 1, 2015 by Leave a Comment
Sales of the new cholesterol-lowering PCSK9 inhibitors have been lower than some had anticipated, the nation’s largest pharmacy benefit manager, Express Scripts, disclosed in a Reuters news story. The majority of prescriptions have been rejected by Express Scripts “because patients did not meet required medical criteria,” Reuters reported. “We’re seeing a lot of patients who either don’t qualify or…
Recent Comments